Month: February 2019

Incremental cost-effectiveness ratio varies across clinical risk groups, sensitive to patient age

But onset before age 50 and migraine without aura not associated with higher risk for stroke

Serum 25(OH)D level <30 ng/mL positively associated with blood glucose level ≥100 mg/dL

Incremental cost-effectiveness ratio varied from $10,000 to $47,000 per QALY for RZV versus no vaccine

Tools offer clinical support for appropriate imaging, symptom assessment, patient education

Mean peer acceptance, physical competence scores lower at ages 3 to 7 compared with controls

Significant negative association identified in male firefighters who were followed for 10 years

Transwomen had higher incidence of strokes, VTEs than reference men and women

Significant survival benefit seen, adverse events similar between darolutamide and placebo

Findings seen with bag-mask ventilation vs. no ventilation for adults undergoing tracheal intubation

Those with positive results should be provided with genetic counseling, testing if indicated

Claims data show many prescribed transmucosal immediate-release fentanyl were opioid-nontolerant

No evidence disease can spread to humans, but hunters should be careful around potentially infected animals

Cases reported in 41 states and the District of Columbia; 107 people have been hospitalized

Expensive ‘fountain of youth’ therapies are unproven, potentially harmful